Can Adagio’s Adintrevimab Hold Up Against Omicron BA.2?

Adagio Therapeutics, Inc. plans to seek an emergency use authorization (EUA) for the monoclonal antibody ADG20 (adintrevimab) for COVID-19 as Phase II/III data have shown it effective at preventing and treating the disease even as the Omicron variant has become prevalent, despite earlier data indicating significantly reduced efficacy against the variant. But its efficacy against a newer, rapidly growing subvariant of Omicron remains uncertain.

Adagio said 30 March that the STAMP trial met its primary endpoint of COVID-19 treatment, while the EVADE trial met its endpoints for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP). The studies met all three primary endpoints with statistical significance